Knowledge Diagram Navigation:

Spatial co-ordinations are initially random, and will automatically re-arrange to minimize complexity based on distance between relationships. Mouse down and drag to pan. Right click on the strategic diagram toggles between motion and stationary. Hover over abstract node (orange) to view abstractions. Hover over leaf node to view corresponding narrative. Left click on the leaf node expands the narrative to view full text.

Narrative Analysis - Report

Key Focus

People with the chronic condition are at heightened risk of cardiovascular disease, Type 2 diabetes, 13 types of cancer, osteoarthritis, asthma and other health problems. ...

Her job with the Los Angeles Unified School District comes with health insurance that covers the pricey drugs and charges her a copay of $30 a month for her Mounjaro prescription. ...

In some parts of the country, Black patients with diabetes are only half as likely as white patients to get GLP-1 drugs, according to research by Dr. ...

Momentum supporting factors

(health,diabetes,risk)

(health,disease,risk)

(diabetes,risk,osteoarthritis)

(health,diabetes,osteoarthritis)

(health,disease,osteoarthritis)

(health,diabetes,los_angeles_unified_school_district)

(health,insurance,los_angeles_unified_school_district)

(health,diabetes,insurance)

(health,disease,diabetes)

(diabetes,risk,chronic)

(health,disease,chronic)

(diabetes,risk,disease)

Challenge supporting factors

(health,university,pennsylvania)

Work-in-progress supporting factors

(health,diabetes,white)

(diabetes,mounjaro)

(health,diabetes,mounjaro)

(health,insurance,mounjaro)

(diabetes,white,glp-1)

(health,diabetes,glp-1)

(health,university,white)

(health,white)

(health,services)

(health,university,services)

(health,university,researcher)

(health,university,pharmaceutical)

(health,university,jigchuan_guo)

(health,university,increased)

(health,insurance,prescribed)

Time Period	Challenge	Momentum	WIP
Report	0.52	14.99	84.50

High Level Abstraction (HLA) combined

High Level Abstraction (HLA)	Report
(1) (health,diabetes,white)	100.00
(2) (health,diabetes,risk)	97.84
(3) (health,disease,risk)	96.76
(4) (diabetes,risk,osteoarthritis)	96.40
(5) (health,diabetes,osteoarthritis)	94.96
(6) (health,disease,osteoarthritis)	93.88
(7) (diabetes,mounjaro)	93.17
(8) (health,diabetes,mounjaro)	92.09
(9) (health,insurance,mounjaro)	90.29
(10) (health,diabetes,los_angeles_unified_school_district)	89.21
(11) (health,insurance,los_angeles_unified_school_district)	87.41
(12) (health,diabetes,insurance)	86.33
(13) (diabetes,white,glp-1)	82.01
(14) (health,diabetes,glp-1)	81.65
(15) (health,university,white)	80.22
(16) (health,white)	79.86
(17) (health,services)	79.50
(18) (health,university,services)	78.42
(19) (health,university,researcher)	78.06
(20) (health,university,pharmaceutical)	77.70
(21) (health,university,pennsylvania)	77.34
(22) (health,university,jigchuan_guo)	76.98
(23) (health,university,increased)	76.62
(24) (health,insurance,prescribed)	75.54
(25) (health,insurance,copay)	75.18
(26) (health,household)	73.74
(27) (health,disease,diabetes)	73.38
(28) (diabetes,risk,chronic)	71.94
(29) (health,disease,chronic)	71.58
(30) (health,south_florida)	70.50
(31) (diabetes,white,eberly)	70.14
(32) (diabetes,glp-1,country)	69.78
(33) (diabetes,white,country)	67.27
(34) (diabetes,white,colleagues)	66.91
(35) (diabetes,risk,food)	66.55
(36) (diabetes,risk,drug_administration)	66.19
(37) (diabetes,risk,disease)	65.47
(38) (diabetes,risk,attacks)	65.11
(39) (diabetes,ozempic)	64.75
(40) (diabetes,glp-1,so-called)	63.67
(41) (diabetes,so-called)	62.95
(42) (diabetes,glp-1,receptor)	62.23
(43) (diabetes,glp-1,day)	61.15
(44) (diabetes,glp-1,agonist)	59.35
(45) (loss,zepbound,drug,fda)	58.27
(46) (diabetes,universal_studios)	57.55
(47) (loss,drug,fda,wegovy)	57.19
(48) (loss,drug,wegovy)	52.52
(49) (loss,zepbound,drug,wegovy)	49.64
(50) (loss,drug,diabetes)	48.20
(51) (loss,drug,fda,diabetes)	45.68
(52) (loss,zepbound,drug,diabetes)	41.01
(53) (loss,drug,tag)	38.49
(54) (loss,zepbound,drug,tag)	35.61
(55) (loss,zepbound,tag)	33.45
(56) (loss,drug,stop)	33.09
(57) (loss,fda,mounjaro)	25.18
(58) (loss,mounjaro)	22.30
(59) (loss,zepbound,fda,mounjaro)	21.22
(60) (loss,zepbound,mounjaro)	18.35
(61) (loss,fda,wegovy)	16.55
(62) (loss,wegovy)	15.11
(63) (loss,zepbound,fda,wegovy)	12.59
(64) (loss,zepbound,wegovy)	11.15
(65) (loss,fda,peptide)	10.07
(66) (loss,zepbound,fda,peptide)	7.19
(67) (loss,zepbound,peptide)	5.76
(68) (loss,fda,insulinotropic)	5.40
(69) (loss,zepbound,fda,insulinotropic)	3.96
(70) (loss,zepbound,insulinotropic)	3.24
(71) (loss,fda,hormone)	2.88
(72) (loss,zepbound,fda,hormone)	1.80
(73) (loss,weight-related)	1.44
(74) (loss,tag)	1.08
(75) (loss,stop)	0.36

Supporting narratives:

Please refer to knowledge diagram for a complete set of supporting narratives.

momentum - Back to HLA

People with the chronic condition are at heightened risk of cardiovascular disease, Type 2 diabetes, 13 types of cancer, osteoarthritis, asthma and other health problems ...
High Level Abstractions:

(diabetes,risk,disease)
(health,diabetes,risk)
(health,disease,risk)
(health,disease,chronic)
(health,disease,diabetes)
(diabetes,risk,chronic)
Inferred entity relationships (9)
(diabetes,health,mounjaro) [inferred]
(diabetes,health,insurance) [inferred]
(diabetes,disease,health) [inferred]
(diabetes,disease,risk) [inferred]
(diabetes,health,los_angeles_unified_school_district) [inferred]
(diabetes,health,white) [inferred]
(diabetes,health,osteoarthritis) [inferred]
(disease,health,risk) [inferred]
(disease,health,osteoarthritis) [inferred]

momentum - Back to HLA

People with the chronic condition are at heightened risk of cardiovascular disease, Type 2 diabetes, 13 types of cancer, osteoarthritis, asthma and other health problems. ...
High Level Abstractions:

(health,disease,osteoarthritis)
(diabetes,risk,osteoarthritis)
(health,diabetes,osteoarthritis)
Inferred entity relationships (6)
(diabetes,health,risk) [inferred]
(diabetes,health,mounjaro) [inferred]
(diabetes,health,white) [inferred]
(diabetes,health,insurance) [inferred]
(diabetes,health,los_angeles_unified_school_district) [inferred]
(disease,health,risk) [inferred]

momentum - Back to HLA

Thanks to the medications, she is no longer on a path toward Type 2 diabetes.. . Her job with the Los Angeles Unified School District comes with health insurance that covers the pricey drugs and charges her a copay of $30 a month for her Mounjaro prescription ...
High Level Abstractions:

(health,diabetes,los_angeles_unified_school_district)
(health,insurance,los_angeles_unified_school_district)
(health,diabetes,insurance)
Inferred entity relationships (9)
(diabetes,health,mounjaro) [inferred]
(diabetes,health,insurance) [inferred]
(diabetes,health,los_angeles_unified_school_district) [inferred]
(health,insurance,mounjaro) [inferred]
(health,insurance,prescribed) [inferred]
(diabetes,health,risk) [inferred]
(diabetes,health,white) [inferred]
(diabetes,health,osteoarthritis) [inferred]
(health,insurance,los_angeles_unified_school_district) [inferred]

challenge - Back to HLA

Lauren Eberly, a cardiologist and health services researcher at the University of Pennsylvania. "I feel like if a group of patients has a disproportionate burden, they should have increased access to these medicines." ...
High Level Abstractions:

(health,university,pennsylvania)

WIP - Back to HLA

In some parts of the country, Black patients with diabetes are only half as likely as white patients to get GLP-1 drugs, according to research by Dr. ...
High Level Abstractions:

(health,diabetes,glp-1)
(health,diabetes,white)
(diabetes,white,glp-1)
Inferred entity relationships (10)
(diabetes,health,mounjaro) [inferred]
(diabetes,glp-1,so-called) [inferred]
(diabetes,health,insurance) [inferred]
(diabetes,glp-1,white) [inferred]
(diabetes,health,los_angeles_unified_school_district) [inferred]
(health,white) [inferred]
(diabetes,health,risk) [inferred]
(diabetes,glp-1,receptor) [inferred]
(diabetes,health,osteoarthritis) [inferred]
(diabetes,glp-1,health) [inferred]

WIP - Back to HLA

Her job with the Los Angeles Unified School District comes with health insurance that covers the pricey drugs and charges her a copay of $30 a month for her Mounjaro prescription. ...
High Level Abstractions:

(diabetes,mounjaro)
(health,insurance,copay)
(health,diabetes,mounjaro)
(health,insurance,mounjaro)
Inferred entity relationships (8)
(diabetes,health,insurance) [inferred]
(diabetes,health,los_angeles_unified_school_district) [inferred]
(health,insurance,mounjaro) [inferred]
(health,insurance,prescribed) [inferred]
(diabetes,health,risk) [inferred]
(diabetes,health,white) [inferred]
(diabetes,health,osteoarthritis) [inferred]
(health,insurance,los_angeles_unified_school_district) [inferred]

WIP - Back to HLA

In some parts of the country, Black patients with diabetes are only half as likely as white patients to get GLP-1 drugs, according to research by Dr. Serena Jigchuan Guo at the University of Florida, who studies health disparities in pharmaceutical access ...
High Level Abstractions:

(health,white)
(health,university,jigchuan_guo)
(health,university,white)

WIP - Back to HLA

"These patients have a higher burden of disease, and they're less likely to get the medicine that can save their lives," said Dr. Lauren Eberly, a cardiologist and health services researcher at the University of Pennsylvania. "I feel like if a group of patients has a disproportionate burden, they should have increased access to these medicines." ...
High Level Abstractions:

(health,university,researcher)
(health,university,services)
(health,services)
Inferred entity relationships (2)
(health,services) [inferred]
(health,services,university) [inferred]

WIP - Back to HLA

Serena Jigchuan Guo at the University of Florida, who studies health disparities in pharmaceutical access. ...
High Level Abstractions:

(health,university,pharmaceutical)

WIP - Back to HLA

"I feel like if a group of patients has a disproportionate burden, they should have increased access to these medicines.". ...
High Level Abstractions:

(health,university,increased)

WIP - Back to HLA

For now, at least, all the new drugs are meant to be taken indefinitely.. . Few health insurance programs cover the medications when prescribed to help people reach and maintain a healthy weight. ...
High Level Abstractions:

(health,insurance,prescribed)
Inferred entity relationships (2)
(health,insurance,los_angeles_unified_school_district) [inferred]
(health,insurance,mounjaro) [inferred]

WIP - Back to HLA

In 2022, the age-adjusted rate was 38.4% for adults with household incomes between $15,000 and $24,999, compared with 34.1% for those with household incomes of $75,000 or more. ...
High Level Abstractions:

(health,household)

WIP - Back to HLA

The disparity was greatest in places with the highest overall usage of the medications, including New York, Silicon Valley and South Florida. ...
High Level Abstractions:

(health,south_florida)

WIP - Back to HLA

In another study of insured patients with Type 2 diabetes, those who were Black were 19% less likely to be treated with these drugs than those who were white, while Latino patients were 9% less likely to get them, Eberly and her colleagues reported. ...
High Level Abstractions:

(diabetes,white,colleagues)
(diabetes,white,eberly)

WIP - Back to HLA

In some parts of the country, Black patients with diabetes are only half as likely as white patients to get GLP-1 drugs, according to research by Dr ...
High Level Abstractions:

(diabetes,glp-1,country)
(diabetes,white,country)
Inferred entity relationships (6)
(diabetes,glp-1,so-called) [inferred]
(country,diabetes,glp-1) [inferred]
(country,diabetes,white) [inferred]
(diabetes,glp-1,receptor) [inferred]
(diabetes,glp-1,white) [inferred]
(diabetes,glp-1,health) [inferred]

WIP - Back to HLA

Ozempic, which is approved by the Food and Drug Administration to help people with Type 2 diabetes control their blood sugar and reduce their risk of serious cardiovascular problems like heart attacks and strokes, has a list price of $968.52 for a 28-day supply ...
High Level Abstractions:

(diabetes,risk,drug_administration)
(diabetes,risk,food)

WIP - Back to HLA

Ozempic, which is approved by the Food and Drug Administration to help people with Type 2 diabetes control their blood sugar and reduce their risk of serious cardiovascular problems like heart attacks and strokes, has a list price of $968.52 for a 28-day supply. ...
High Level Abstractions:

(diabetes,risk,attacks)

WIP - Back to HLA

The first so-called GLP-1 receptor agonist was approved in 2005 to treat diabetes, and early versions had to be injected once or twice a day. Ozempic improved on this by requiring an injection only once a week. ...
High Level Abstractions:

(diabetes,ozempic)

WIP - Back to HLA

. The first so-called GLP-1 receptor agonist was approved in 2005 to treat diabetes, and early versions had to be injected once or twice a day ...
High Level Abstractions:

(diabetes,glp-1,so-called)
(diabetes,glp-1,receptor)
(diabetes,so-called)
(diabetes,glp-1,agonist)
Inferred entity relationships (4)
(diabetes,glp-1,so-called) [inferred]
(diabetes,glp-1,receptor) [inferred]
(diabetes,glp-1,white) [inferred]
(diabetes,glp-1,health) [inferred]

WIP - Back to HLA

The first so-called GLP-1 receptor agonist was approved in 2005 to treat diabetes, and early versions had to be injected once or twice a day. ...
High Level Abstractions:

(diabetes,glp-1,day)
Inferred entity relationships (4)
(diabetes,glp-1,so-called) [inferred]
(diabetes,glp-1,receptor) [inferred]
(diabetes,glp-1,white) [inferred]
(diabetes,glp-1,health) [inferred]

WIP - Back to HLA

She is no longer breathless when she climbs stairs, has an easier time when she goes bowling and fits comfortably into the seat on the Harry Potter ride at Universal Studios. Thanks to the medications, she is no longer on a path toward Type 2 diabetes. ...
High Level Abstractions:

(diabetes,universal_studios)

WIP - Back to HLA

After clinical trials showed that the drug helped people with obesity achieve substantial, sustainable weight loss, the FDA approved Wegovy as a weight management drug in 2021. ...
High Level Abstractions:

(loss,zepbound,drug,wegovy)
(loss,drug,fda,wegovy)
(loss,zepbound,drug,fda)
(loss,drug,wegovy)
Inferred entity relationships (15)
(drug,loss,wegovy) [inferred]
(fda,loss,wegovy) [inferred]
(loss,wegovy,zepbound) [inferred]
(fda,loss,peptide) [inferred]
(fda,loss,wegovy,zepbound) [inferred]
(drug,fda,loss,wegovy) [inferred]
(drug,loss,wegovy,zepbound) [inferred]
(loss,wegovy) [inferred]
(fda,loss,mounjaro,zepbound) [inferred]
(drug,fda,loss,zepbound) [inferred]
(drug,loss,tag) [inferred]
(drug,loss,stop) [inferred]
(fda,loss,mounjaro) [inferred]
(fda,loss,peptide,zepbound) [inferred]
(drug,loss,tag,zepbound) [inferred]

WIP - Back to HLA

Mounjaro is a similar drug approved by the FDA to improve blood sugar levels in Type 2 diabetes patients, and it comes with a list price of $1,069.08 for 28 days of medicine ...
High Level Abstractions:

(loss,drug,diabetes)
(loss,zepbound,drug,diabetes)
(loss,zepbound,drug,fda)
(loss,drug,fda,diabetes)
Inferred entity relationships (16)
(drug,loss,wegovy) [inferred]
(diabetes,drug,loss) [inferred]
(fda,loss,wegovy) [inferred]
(diabetes,drug,fda,loss) [inferred]
(drug,fda,loss,wegovy) [inferred]
(fda,loss,peptide) [inferred]
(fda,loss,wegovy,zepbound) [inferred]
(drug,loss,wegovy,zepbound) [inferred]
(fda,loss,mounjaro,zepbound) [inferred]
(drug,fda,loss,zepbound) [inferred]
(drug,loss,tag) [inferred]
(drug,loss,stop) [inferred]
(fda,loss,mounjaro) [inferred]
(diabetes,drug,loss,zepbound) [inferred]
(fda,loss,peptide,zepbound) [inferred]
(drug,loss,tag,zepbound) [inferred]

WIP - Back to HLA

Zepbound, a version of the same drug approved for weight loss, has a slightly lower price tag of $1,059.87 per 28 days. ...
High Level Abstractions:

(loss,zepbound,tag)
(loss,drug,tag)
(loss,zepbound,drug,tag)
Inferred entity relationships (7)
(drug,loss,wegovy) [inferred]
(loss,tag) [inferred]
(drug,loss,tag) [inferred]
(drug,loss,stop) [inferred]
(drug,loss,wegovy,zepbound) [inferred]
(loss,tag,zepbound) [inferred]
(drug,loss,tag,zepbound) [inferred]

WIP - Back to HLA

She said she could swing a monthly payment of up to $50, but beyond that she'd have to stop taking the drug and hope the lifestyle changes she'd made would be enough to sustain the weight loss she's achieved so far ...
High Level Abstractions:

(loss,drug,stop)
Inferred entity relationships (5)
(drug,loss,wegovy) [inferred]
(drug,loss,tag) [inferred]
(loss,stop) [inferred]
(drug,loss,wegovy,zepbound) [inferred]
(drug,loss,tag,zepbound) [inferred]

WIP - Back to HLA

After clinical trials showed that the drug helped people with obesity achieve substantial, sustainable weight loss, the FDA approved Wegovy as a weight management drug in 2021.. . Mounjaro and Zepbound also mimic GLP-1, along with a related hormone called glucose-dependent insulinotropic peptide, or GIP ...
High Level Abstractions:

(loss,fda,mounjaro)
(loss,zepbound,fda,mounjaro)
(loss,wegovy)
(loss,zepbound,fda,wegovy)
(loss,mounjaro)
(loss,fda,wegovy)
(loss,zepbound,wegovy)
(loss,zepbound,mounjaro)
Inferred entity relationships (10)
(fda,loss,wegovy) [inferred]
(loss,wegovy,zepbound) [inferred]
(fda,loss,peptide) [inferred]
(fda,loss,wegovy,zepbound) [inferred]
(loss,wegovy) [inferred]
(fda,loss,mounjaro,zepbound) [inferred]
(loss,mounjaro) [inferred]
(loss,mounjaro,zepbound) [inferred]
(fda,loss,mounjaro) [inferred]
(fda,loss,peptide,zepbound) [inferred]

WIP - Back to HLA

Mounjaro and Zepbound also mimic GLP-1, along with a related hormone called glucose-dependent insulinotropic peptide, or GIP. ...
High Level Abstractions:

(loss,zepbound,peptide)
(loss,fda,peptide)
(loss,zepbound,fda,insulinotropic)
(loss,zepbound,fda,peptide)
(loss,zepbound,insulinotropic)
(loss,fda,insulinotropic)
Inferred entity relationships (10)
(fda,loss,wegovy) [inferred]
(fda,loss,wegovy,zepbound) [inferred]
(fda,loss,peptide) [inferred]
(fda,loss,mounjaro,zepbound) [inferred]
(fda,insulinotropic,loss,zepbound) [inferred]
(insulinotropic,loss,zepbound) [inferred]
(fda,loss,mounjaro) [inferred]
(loss,peptide,zepbound) [inferred]
(fda,loss,peptide,zepbound) [inferred]
(fda,insulinotropic,loss) [inferred]

WIP - Back to HLA

After clinical trials showed that the drug helped people with obesity achieve substantial, sustainable weight loss, the FDA approved Wegovy as a weight management drug in 2021.. . Mounjaro and Zepbound also mimic GLP-1, along with a related hormone called glucose-dependent insulinotropic peptide, or GIP. ...
High Level Abstractions:

(loss,zepbound,fda,hormone)
(loss,fda,hormone)
Inferred entity relationships (2)
(fda,hormone,loss,zepbound) [inferred]
(fda,hormone,loss) [inferred]

WIP - Back to HLA

Wegovy, a higher dose of the same medicine that's FDA-approved for weight loss in people with obesity or who are overweight and have a weight-related condition like high blood pressure or high cholesterol, goes for $1,349.02 every four weeks ...
High Level Abstractions:

(loss,weight-related)

WIP - Back to HLA

Zepbound, a version of the same drug approved for weight loss, has a slightly lower price tag of $1,059.87 per 28 days. For now, at least, all the new drugs are meant to be taken indefinitely ...
High Level Abstractions:

(loss,tag)
Inferred entity relationships (1)
(loss,tag,zepbound) [inferred]

WIP - Back to HLA

She said she could swing a monthly payment of up to $50, but beyond that she'd have to stop taking the drug and hope the lifestyle changes she'd made would be enough to sustain the weight loss she's achieved so far. ...
High Level Abstractions:

(loss,stop)

Semantics Relevance

'Miracle'weight-loss drugs could have reduced health disparities. ...